1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
137.32 USD   +4.29%
05/17BeiGene to Open Regional Office in Switzerland
MT
05/17BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
BU
05/17BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
129.18(c) 138.58(c) 131.09(c) 131.67(c) 137.32 Last
228 845 191 194 286 151 361 490 259 493 Volume
-2.78% +7.28% -5.40% +0.44% +4.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 429 M - -
Net income 2022 -1 407 M - -
Net cash position 2022 2 668 M - -
P/E ratio 2022 -8,87x
Yield 2022 -
Sales 2023 2 108 M - -
Net income 2023 -1 051 M - -
Net cash position 2023 1 449 M - -
P/E ratio 2023 -9,80x
Yield 2023 -
Capitalization 13 585 M 13 585 M -
EV / Sales 2022 7,64x
EV / Sales 2023 5,76x
Nbr of Employees 8 300
Free-Float 99,0%
More Financials
Company
Beigene Ltd is a biotechnology company in the commercial stage. The Company focuses on research and development (R&D), production and commercialization of innovative drugs. The Company has three products approved for listing, including Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). The Company also has eight products in clinical stage, including BGB-283, BGB-A333, BGB-A425, BGB-A1217,... 
More about the company
Ratings of BeiGene, Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about BEIGENE, LTD.
05/17BeiGene to Open Regional Office in Switzerland
MT
05/17BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
BU
05/17BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
MT
05/09INSIDER SELL : BeiGene
MT
05/09BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/05BeiGene Swings to Q1 Net Loss as Revenue Declines
MT
05/05Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M
MT
05/05BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
05/05BeiGene Reports First Quarter 2022 Financial Results
BU
05/05BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/04BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute..
MT
More news
News in other languages on BEIGENE, LTD.
05/17BeiGene, Ltd. annonce l'ouverture d'un nouveau bureau régional à Bâle, en Suisse
05/11Les ADR asiatiques progressent dans les échanges de mercredi
05/10Les ADR asiatiques grimpent dans les échanges de mardi
05/09VENTE D'INITIÉS : BeiGene
05/05BeiGene subit une perte nette au premier trimestre en raison d'une baisse du chiffre d'..
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 131,67 $
Average target price 312,07 $
Spread / Average Target 137%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-51.40%13 585
GILEAD SCIENCES, INC.-12.86%79 360
REGENERON PHARMACEUTICALS, INC.4.06%70 805
VERTEX PHARMACEUTICALS16.33%65 333
WUXI APPTEC CO., LTD.-19.12%41 354
BIONTECH SE-34.88%40 796